Suzhou Highfine Biotech Past Earnings Performance
Past criteria checks 2/6
Suzhou Highfine Biotech has been growing earnings at an average annual rate of 10.3%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 4.3% per year. Suzhou Highfine Biotech's return on equity is 4.8%, and it has net margins of 26.3%.
Key information
10.3%
Earnings growth rate
6.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 4.3% |
| Return on equity | 4.8% |
| Net Margin | 26.3% |
| Next Earnings Update | 30 Oct 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Suzhou Highfine Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 404 | 106 | 45 | 34 |
| 31 Mar 24 | 355 | 93 | 37 | 34 |
| 31 Dec 23 | 389 | 99 | 36 | 28 |
| 30 Sep 23 | 390 | 105 | 33 | 26 |
| 30 Jun 23 | 387 | 114 | 26 | 21 |
| 31 Mar 23 | 437 | 128 | 26 | 21 |
| 01 Jan 23 | 447 | 129 | 25 | 22 |
| 30 Sep 22 | 465 | 134 | 26 | 21 |
| 30 Jun 22 | 480 | 136 | 29 | 21 |
| 31 Mar 22 | 425 | 124 | 27 | 18 |
| 31 Dec 21 | 369 | 111 | 26 | 15 |
| 31 Dec 20 | 282 | 40 | 50 | 22 |
| 31 Dec 19 | 191 | 58 | 17 | 8 |
| 31 Dec 18 | 142 | 40 | 13 | 7 |
| 30 Sep 18 | 132 | 38 | 11 | 8 |
| 30 Jun 18 | 122 | 31 | 17 | 1 |
| 31 Mar 18 | 108 | 27 | 17 | 0 |
| 31 Dec 17 | 94 | 23 | 9 | 7 |
| 30 Sep 17 | 93 | 22 | 10 | 5 |
| 30 Jun 17 | 93 | 22 | 11 | 3 |
| 31 Mar 17 | 90 | 20 | 13 | 2 |
| 31 Dec 16 | 88 | 19 | 14 | 0 |
| 30 Sep 16 | 82 | 16 | 13 | 0 |
| 30 Jun 16 | 77 | 14 | 13 | 0 |
| 31 Mar 16 | 71 | 12 | 12 | 0 |
| 31 Dec 15 | 66 | 9 | 12 | 0 |
| 31 Dec 14 | 50 | 3 | 9 | 0 |
| 31 Dec 13 | 34 | 2 | 8 | 0 |
Quality Earnings: 301393 has high quality earnings.
Growing Profit Margin: 301393's current net profit margins (26.3%) are lower than last year (29.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 301393's earnings have grown by 10.3% per year over the past 5 years.
Accelerating Growth: 301393's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 301393 had negative earnings growth (-6.6%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-0.6%).
Return on Equity
High ROE: 301393's Return on Equity (4.8%) is considered low.